Vertex Pharmaceuticals Inc
VRTX· Nasdaq
Released Aug 1, 2024, after the close
10-Q filed Aug 2, 2024, 33 days after period end · 0000875320-24-000198
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $2.65B | $2.49B | $2.20B | $1.79B |
| Net Income | -$3.59B | $915.70M | $810.50M | $67.00M |
| EPS Diluted |
Vertex Pharmaceuticals Inc · CIK 875320 · Engraved from SEC EDGAR
| -$13.92 |
| $3.52 |
| $3.13 |
| $0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.